The Impact of Excessive Dietary Sodium on Brain Health
1 other identifier
observational
220
1 country
1
Brief Summary
Sporadic cerebral small vessel disease (CSVD) is not only the most common subtype of vascular dementia, in recent multi-center study showed that sporadic CSVD harbors in a third of Alzheimer's disease (AD) patients in 9 Asian regions. The CSVD increases the severity of cognitive impairment in these patients and has an etiological contribution to the development of AD. Studies demonstrated that CSVD is more prevalent in Chinese than in Australians and this association was independent of traditional vascular risk factors (e.g. hypertension). Other factors such as lifestyle, environmental or genetic factors may explain this difference. Although hypertension is an important cause for CSVD, it only accounts for a small proportion of the variance in CSVD. Irrespective of the cause, it is currently believed that endothelial dysfunction of CSVD is the key pathophysiological mechanism of CSVD. Having an effective treatment of CSVD will have an enormous impact on the prevention of dementia. Excessive dietary sodium is an established risk factor for cardiovascular diseases, including stroke. It is traditionally linked to its effects in raising blood pressure. The Department of Health advocated reducing salt intake for the prevention of hypertension, coronary heart disease, and stroke. However, recent epidemiological studies suggest that it may have a direct effect on cardiovascular diseases independent of blood pressure. A recent animal study showed that excessive dietary sodium-induced cerebral endothelial dysfunction, resulting in cognitive impairment. Interestingly, endothelial dysfunction was related to an adaptive immune response in the gut. A clinical study conducted in the United Kingdom suggested excessive dietary sodium intake may promote CSVD A clinical study conducted in the United Kingdom suggested excessive dietary sodium intake may promote CSVD by increasing WMH volume in the brain, independent of its effects on blood pressure. Notably, a few animal studies showed that the association between high dietary sodium and worse cognitive function in the absence of blood pressure changes. This pinpoints the important role of dietary sodium as an independent contributor to brain health and cognition. This study aims to assess the association between dietary sodium, neuroimaging measures, and cognition in cerebral small vessel disease and controls during the 18-month follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 10, 2022
CompletedFirst Posted
Study publicly available on registry
May 13, 2022
CompletedStudy Start
First participant enrolled
June 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2025
CompletedFebruary 15, 2024
February 1, 2024
2.9 years
May 10, 2022
February 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (15)
Change of level of urinary sodium
24 hours of urine will be collected to measure the level of sodium The higher the sodium level the worse the outcome
Baseline and 18 month
Change of Gait
Gait velocity will be assessed using the 8-meter walking time. Time for walking 8-m will be measured by a stopwatch. The faster of two trials will be used in the analysis The faster of the walking time the better outcome.
Baseline and 18 month
Change of balance
Single leg stance time will be measured by asking participants, with their hands on their hips, to balance as long as possible on one leg with an upper limit of 30 seconds. Two trials for each leg will be performed. The best time of the four trials will be used for analysis. The longer the time duration the better outcome.
Baseline and 18 month
Change of Hong Kong MOntreal Cognitive Assessment
Hong Kong MOntreal Cognitive Assessment (HK-MoCA) is a cognitive assessmenttool. Score from 0 to 30 . The lower score reflect the worse the outcome.
Baseline and 18 month
Change of The Chinese Geriatric Depression Scale 30
The Chinese Geriatric Depression Scale is used to detect depressive mood. Score 0 to 30. The higher the score, the worse the outcome
Baseline and 18 month
Change of Pittsburgh sleep quality index
Pittsburgh sleep quality index Chinese Version is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The questionnaire contains frequency questions related to sleep quality, each question scale from 0 to 3. The higher the score, the worse the outcome. There is no total score available for this assessment
Baseline and 18 month
Change of Hong Kong List Learning Test
Hong Kong List Learning Test is memory test in Chinese designed for the assessment of the processes and organizational strategies involved in learning verbal information. The more negative the standard deviation the worse the outcome
Baseline and 18 month
Food frequency questionnaire
The food frequency questionnaire serves the purpose of understanding the type of food that subject frequently consume in the past 12 months. There is no total score for this assessment. There is no positive and negative outcome available
Baseline
Food frequency questionnaire
The food frequency questionnaire serves the purpose of understanding the type of food that subject frequently consume in the past 12 months. There is no total score for this assessment. There is no positive and negative outcome available
18 month
24 hour food intake
The 24 hour food intake serves the purpose of understanding the food that subject consume on the day of urine collection There is no positive and negative outcome available
Baseline
24 hour food intake
The 24 hour food intake serves the purpose of understanding the food that subject consume on the day of urine collection There is no positive and negative outcome available
18 Month
Change of creatinine in urine
24 hours of urine will be collected to measure the level of creatinine The higher the creatinine level the worse the outcome
Baseline and 18 month
change of urinary potassium
24 hours of urine will be collected to measure the level of potassium The higher the potassium level the worse the outcome
Baseline and 18 month
Change of International Physical Activity Questionnaire
the International Physical Activity Questionnaire is a self report assessment to investigate the daily activities (frequency, duration, and level) of subject within the 7 days prior assessment There is no total score available for this questionnaire. The higher duration and frequency and level of daily activities the better outcome
Baseline and 18 month
Change of Brain Peak Width of Skeletonized Mean Diffusivity
Peak Width of Skeletonized Mean Diffusivity is a robust, fully-automated and easy-to-implement marker for cerebral small vessel disease based on diffusion tensor imaging, white matter tract skeletonization and histogram analysis. It is a biomarker for brain MRI images.
Baseline and 18 month
Secondary Outcomes (1)
Change of 24 hour blood pressure monitoring
Baseline and 18 Month
Eligibility Criteria
Subject with cSVD will be recruited at stroke unit and neurology clinic at Prince of Wales Hospital. Healthy volunteers will recruited through other community cohorts.
You may qualify if:
- Chinese ethnicity,
- age between 55 and 80-year-old, and
- a primary language of Cantonese.
- Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI;
- Modified Functional Ambulation Classification 5 or above;
- Montreal Cognitive Assessment (MoCA) score \< 25;
You may not qualify if:
- Hypernatremia (Na \>146mmol/L) or hyponatremia (Na \<134 mmol/L) from screening blood test;
- With sodium supplement;
- Renal failure (stage 4 \& 5) with glomerular filtration rate \< 29;
- performed cardiac surgery or neurosurgery, with cardiac failure;
- Had major psychiatric diseases
- Contraindications for MRI.
- Dementia or MoCA score lower than 2nd percentile of the age and education adjusted cutoff ;
- Cerebral white matter changes unrelated to neurodegenerative, e.g. CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, multiple sclerosis, etc.\|
- Contraindication to proposed imaging, e.g. chronic kidney disease (KDNIGO) stage 4 or above, acute kidney injury, hypersensitivity to gadolinium-based contrast, non-MRI conditional implants or prosthesis
- Medical condition that would not allow the patient to adhere to the protocol or complete the study.;
- Patient with established neurodegenerative disorders (e.g. Parkinson's Disease, Alzheimer's Disease, etc.);
- Pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prince of Wales Hospital
Shatin, N.T., 00000, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bonnie Yin Ka Lam, PhD
Chinese University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Assistant Professor
Study Record Dates
First Submitted
May 10, 2022
First Posted
May 13, 2022
Study Start
June 22, 2022
Primary Completion
May 1, 2025
Study Completion
October 30, 2025
Last Updated
February 15, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share